Table 4.
Risk factors for overall and progression fee survival in stage III locally advanced pancreatic cancer patients.
| Characteristic | KM Median (95% CI) | P value |
|---|---|---|
| OS from diagnosis | ||
| CA19-9 change from diagnosis to IRE | 0.03 | |
| Abnormal to normal | 30.2 (22.5-43.5) | |
| Abnormal to abnormal | 18.8 (15.4-22.7) | |
| Vascular involvement | ||
| ≤ 180° | 52.8 (17.7-90.8) | 0.006 |
| > 180° | 22.7 (18.4-24.7) | |
| Prior chemotherapy duration | ||
| > 5 months | 23.1 (17.4-34.7) | 0.04 |
| ≤ 5 months | 21.7 (15.7-24.4) | |
| OS from IRE | ||
| Age | 0.02 | |
| ≤ 61 | 23.9 (10-49.7) | |
| > 61 | 18.2 (13.3-23.1) | |
| CA19-9 change from diagnosis to IRE | 0.02 | |
| Normal at IRE (≤ 37 U/mL) | 17.5 (12.4-22.8) | |
| Abnormal at IRE (> 37 U/mL) | 9.3 (5.9-13.3) | |
| Diabetes | 0.003 | |
| Yes | 13.3 (6.4-14.8) | |
| No | 23.1 (22.0-31.2) | |
| Vascular involvement | 0.01 | |
| ≤ 180° | 52.5 (4.8-52.5) | |
| > 180° | 12.4 (6.6-16.4) | |
| Number of comorbidities | 0.04 | |
| ≤ 2 | 21.6 (10.3-23.9) | |
| > 2 | 12.4 (6.6-16.4) | |
| Prior chemotherapy | 0.01 | |
| FOLFIRINOX + gemcitabine/abraxane | 23.2 (19.4-35.9) | |
| FOLFIRINOX | 13.3 (9.4-18.2) | |
| Gemcitabine/abraxane | 12.4 (4.6-26.5) | |
| Prior radiation | <0.0001 | |
| Yes | 12.3 (6.4-17.2) | |
| No | 26.5 (22.7-6.3) | |
| Tumor size | 0.0003 | |
| ≤ 3.6 | 26.5 (22.5-2.5) | |
| > 3.6 | 18.2 (13.8-22.8) | |
| PFS from diagnosis | ||
| Vascular involvement | 0.001 | |
| ≤ 180° | 52.8 (17.5-77.1) | |
| > 180° | 16.8 (15.7-18.4) | |
| Prior chemotherapy | 0.04 | |
| FOLFIRINOX + Gemcitabine/abraxane | 20.8 (17.5-24.7) | |
| FOLFIRINOX | 18.7 (16.3-20.7) | |
| Gemcitabine/abraxane | 15.5 (10.6-25.4) | |
| PFS from IRE | ||
| Age | 0.046 | |
| ≤ 61 | 22.0 (18.8-30.4) | |
| > 61 | 12.5 (8.9-186) | |
| CA19-9 | ||
| Normal at IRE | 8.9 (7.0-11.5) | 0.006 |
| Abnormal at IRE | 5.3 (3.7-6.6) | |
| Diabetes | 0.0003 | |
| Yes | 7.2 (4.3-13.8) | |
| No | 20.6 (14.6-22.8) | |
| Vascular involvement | 0.005 | |
| ≤ 180° | 24.2 (4.5-52.5) | |
| > 180° | 7.3 (5.8-8.8) | |
| Prior chemotherapy | <0.0001 | |
| FOLFIRINOX + gemcitabine/abraxane | 19.4 (14.5-23.2) | |
| FOLFIRINOX | 8.7 (5.8-11.5) | |
| Gemcitabine/abraxane | 8.8 (2.9-10.9) | |
| Preoperative radiation | <0.0001 | |
| Yes | 6.7 (3.3-8.9) | |
| No | 22.3 (18.9-29.3) | |
| Tumor size (cm) | <0.0001 | |
| ≤ 3.6 | 22.8 (19.4-35.9) | |
| > 3.6 | 10.4 (8.2-6.1) | |
OS, overall survival; KM, Kaplan Meier; CA19-9, cancer antigen 19-9; IRE, irreversible electroporation; PFS, progression free survival; FOLFIRINOX, folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin.
Bold values represent statistical significance with p values less than 0.05.